Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Gene editing pioneer Editas agrees US$90m collaboration with Allergan

Tuesday, March 14, 2017 7:57
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Editas Medicine Inc (NASDAQ:EDIT) shares jumped 11% as it tied up a research deal for its pioneering gene-editing treatments with giant pharma Allergan PLC (NYSE:AGN).

The Dublin-based maker of Botox has paid US$90mln for an exclusive option on five of Editas’s development programmes including its flagship pre-clinical programme for Leber Congenital Amaurosis or LCA10.

The condition is the most common cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide.

Allergan will additional royalty and commercial payments if  Editas’ LCA10 programme proves commercial.

Editas is best known as one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR, which is seen as potentially heralding the next step forward in a whole range of treatments.

Along with Botox, eyecare, emanwhile, is a key part of  Allergan’s aesthetics business.

“Allergan has long been a leader in advancing innovative therapies to treat eye diseases,” said Katrine Bosley, Editas’s chief executive.

“Working together with Allergan through their Open Science R&D model significantly enhances our ability to develop genome editing medicines to help patients with serious eye diseases.”

Editas shares rose to US$26.9.

Story by ProactiveInvestors


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.